Jonathan McNeill - 09 Jan 2023 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Senior Vice President of Business Development
Signature: /s/ Richard Scalzo, Attorney-in-Fact
Issuer symbol: DYN
Transactions as of: 09 Jan 2023
Transactions value $: -$348,836
Form type: 4
Filing time: 11 Jan 2023, 15:56:59 UTC
Previous filing: 13 Dec 2022
Next filing: 23 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DYN	Common Stock	Sale	-$348,835	-30,150	-31%	$11.57	67,600	09 Jan 2023	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.12 to $11.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4.
F3	Includes 67,490 unvested RSUs.

Remarks:

Senior Vice President of Business Development